We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Investigation of Plasma Proteins in Patients With Hereditary Haemorrhagic Telangiectasia and PAVMs

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2008 by Imperial College London.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00230672
First Posted: October 3, 2005
Last Update Posted: August 13, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Imperial College London
  Purpose
Hereditary Haemorrhagic Telangiectasia (HHT, also known as Osler-Weber-Rendu Syndrome) is an disease that leads to the development of dilated and fragile blood vessels, including arteriovenous malformations in the lungs (PAVMs). We hypothesize that the genetically-determined abnormality in the blood vessels of HHT patients leads to alteration in the concentrations or activity of several proteins in the blood stream. We propose to take blood samples from patients at defined times in order to study changes in blood protein levels and activity

Condition
Telangiectasia, Hereditary Hemorrhagic

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Studies of Plasma Proteins Derived From Pulmonary Arteriovenous Malformation Patients

Resource links provided by NLM:


Further study details as provided by Imperial College London:

Estimated Enrollment: 70
Study Start Date: March 2005
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Patients with hereditary haemorrhagic telangiectasia and pulmonary arteriovenous malformations -

Exclusion Criteria:Unable to provide informed consent

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00230672


Contacts
Contact: Claire Shovlin 0208 383 1000 c.shovlin@imperial.ac.uk

Locations
United Kingdom
Imperial College Hammersmith Campus Recruiting
London, United Kingdom, W12 0NN
Contact: Claire Shovlin    0208 383 1000    c.shovlin@imperial.ac.uk   
Sponsors and Collaborators
Imperial College London
Investigators
Principal Investigator: Claire Shovlin Imperial College London
  More Information

ClinicalTrials.gov Identifier: NCT00230672     History of Changes
Other Study ID Numbers: IC/CLS7
First Submitted: September 29, 2005
First Posted: October 3, 2005
Last Update Posted: August 13, 2008
Last Verified: August 2008

Additional relevant MeSH terms:
Telangiectasis
Arteriovenous Malformations
Telangiectasia, Hereditary Hemorrhagic
Vascular Diseases
Cardiovascular Diseases
Vascular Malformations
Cardiovascular Abnormalities
Congenital Abnormalities
Hemostatic Disorders
Hemorrhagic Disorders
Hematologic Diseases